Author:
Bartlett R. R.,Dimitrijevic M.,Mattar T.,Zielinski T.,Germann T.,Rüde E.,Thoenes G. H.,Küchle C. C. A.,Schorlemmer H. -U.,Bremer E.,Finnegan A.,Schleyerbach R.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Toxicology,Pharmacology,Immunology
Reference44 articles.
1. R. R. Bartlett, T. Mattar, U. Weithmann, H. Anagnostopulos, S. Popovic and R. Schleyerbach,Leflunomide (HWA 486): a novel immunorestoring drug. InTherapeutic approaches to inflammatory diseases (Eds. A. J. Lewis, N. S. Doherty and N. R. Ackerman), Elsevier Science Publishing Co., Inc. New York, pp. 215–228 (1989).
2. R. R. Bartlett and R. Schleyerbach,Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity I. Disease modifying action on adjuvant arthritis of the rat. Int J. Immunopharmac.7, 7–18 (1985).
3. R. R. Bartlett, R. X. Raiss, S. Popovic and R. Schleyerbach,Immunologic, histologic and ultrastructural studies in autoimmune MRL/1 mice. InArticular cartilage biochemistry (Eds. K. E. Kuettner, R. Schleyerbach and V. C. Hascall), pp. 391–412 (1986).
4. S. Popovic and R. R. Bartlett,Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents and Actions19, 313–314 (1986).
5. S. Popovic and R. R. Bartlett,The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents and Actions21, 284–286 (1987).
Cited by
176 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献